These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30564288)

  • 1. Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes.
    Zhang WQ; Tian Y; Chen XM; Wang LF; Chen CC; Qiu CM
    Diabetol Metab Syndr; 2018; 10():91. PubMed ID: 30564288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes.
    Chen XM; Zhang WQ; Tian Y; Wang LF; Chen CC; Qiu CM
    Cardiovasc Diabetol; 2018 Apr; 17(1):53. PubMed ID: 29636047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
    von Herrath M; Bain SC; Bode B; Clausen JO; Coppieters K; Gaysina L; Gumprecht J; Hansen TK; Mathieu C; Morales C; Mosenzon O; Segel S; Tsoukas G; Pieber TR;
    Lancet Diabetes Endocrinol; 2021 Apr; 9(4):212-224. PubMed ID: 33662334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of serum 25-hydroxyvitamin D3 on insulin resistance and β-cell function in newly diagnosed type 2 diabetes patients.
    Yang Y; Zhang X; Bao M; Liu L; Xian Y; Wu J; Li P
    J Diabetes Investig; 2016 Mar; 7(2):226-32. PubMed ID: 27042275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
    Anholm C; Kumarathurai P; Pedersen LR; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Diabetes Obes Metab; 2017 Jun; 19(6):850-857. PubMed ID: 28124822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease.
    Liu Y; Jiang X; Chen X
    Lipids Health Dis; 2017 Dec; 16(1):227. PubMed ID: 29197387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Anholm C; Kumarathurai P; Pedersen LR; Samkani A; Walzem RL; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Atherosclerosis; 2019 Sep; 288():60-66. PubMed ID: 31326727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
    Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
    Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rosiglitazone on inflammatory cytokines and oxidative stress after intensive insulin therapy in patients with newly diagnosed type 2 diabetes.
    Li J; Shen X
    Diabetol Metab Syndr; 2019; 11():35. PubMed ID: 31073335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of islet beta cell function in subjects with normal glucose tolerance, impaired glucose regulation, and type 2 diabetes mellitus].
    Liu J; Li YB; Shao H; Li YX; Yuan YH; Xiao YB; Weng JP
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(18):1252-5. PubMed ID: 17686259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
    Tian F; Zheng Z; Zhang D; He S; Shen J
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
    Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
    Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.
    Anholm C; Kumarathurai P; Klit MS; Kristiansen OP; Nielsen OW; Ladelund S; Madsbad S; Sajadieh A; Haugaard SB;
    BMJ Open; 2014 Jul; 4(7):e005942. PubMed ID: 25031198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).
    Nomoto H; Miyoshi H; Furumoto T; Oba K; Tsutsui H; Miyoshi A; Kondo T; Tsuchida K; Atsumi T; Manda N; Kurihara Y; Aoki S;
    PLoS One; 2015; 10(8):e0135854. PubMed ID: 26284918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
    Arturi F; Succurro E; Miceli S; Cloro C; Ruffo M; Maio R; Perticone M; Sesti G; Perticone F
    Endocrine; 2017 Sep; 57(3):464-473. PubMed ID: 27830456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Anholm C; Kumarathurai P; Samkani A; Pedersen LR; Boston RC; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Diabetes Obes Metab; 2019 Aug; 21(8):2012-2016. PubMed ID: 31050161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells.
    Batchuluun B; Inoguchi T; Sonoda N; Sasaki S; Inoue T; Fujimura Y; Miura D; Takayanagi R
    Atherosclerosis; 2014 Jan; 232(1):156-64. PubMed ID: 24401231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.
    Forst T; Michelson G; Ratter F; Weber MM; Anders S; Mitry M; Wilhelm B; Pfützner A
    Diabet Med; 2012 Sep; 29(9):1115-8. PubMed ID: 22288732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.